Purpose of this Study
We are doing this study to compare the performance of 2 drugs: zanzalintinib and everolimus. We want to know which option is the most effective for treating neuroendocrine tumors.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with locally advanced (cannot be removed by surgery) or metastatic (has spread) neuroendocrine tumor
- Have failed to adequately respond to previous treatment
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join the study, you will get a random assignment (like a coin flip) to either take zanzalintinib or everolimus once per day. Both drugs are taken by mouth.
Your study regimen will last for as long as the study doctor believes that you are getting a positive benefit.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic
neuroendocrine tumors (XL092-311)
neuroendocrine tumors (XL092-311)
Principal Investigator
Michael
Morse
Protocol Number
PRO00118100
NCT ID
NCT06943755
Phase
II/III
Enrollment Status
Pending Open to Enrollment